The AI-powered financial markets research terminal for institutional investors.

Stay Updated

Research

Analysis & Automation

Financial Services

Corporations

H.C. Wainwright reiterates CRISPR Therapeutics stock rating at buy | AllMind News

H.C. Wainwright reiterates CRISPR Therapeutics stock rating at buy

August 31, 2026

Article content was unavailable (received only '403'), so no news details, figures, or impacts could be extracted.

Analysis

Article content was unavailable (received only '403'), so no news details, figures, or impacts could be extracted.

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Overall Sentiment

neutral

Sentiment Score

0.00

Markets see Warsh endorsing a rate hike in September. Not everyone is convincedAugust 31, 2026
FTC sues Amazon, accusing the ecommerce giant of misleading advertisersAugust 31, 2026
Trump announced a massive oil deal with Venezuela. Why it won't lower gas prices anytime soonAugust 31, 2026
Ten-Year Yield Jumps To Highest Closing Level Since January 2025August 31, 2026
Lilly taps obesity windfall for more M&A. Plus, Elon Musk remarks pull GE Vernova lowerAugust 31, 2026
Amazon’s stock slips as the FTC alleges billions of dollars in hidden ad feesAugust 31, 2026